Literature DB >> 11383485

Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine.

J J Orrego1, W F Chandler, A L Barkan.   

Abstract

Prolactin (PRL)-secreting pituitary adenomas are the most common functioning pituitary tumors. Medical treatment with dopamine agonists is the therapy of choice for macroprolactinomas (> or = 10 mm). Withdrawal of bromocriptine after weeks or months of uninterrupted therapy has been associated with rapid tumor re-expansion as evidenced by x-ray and CT scanning of the pituitary region. We report a patient with a giant macroprolactinoma who had a dramatic response to bromocriptine (tumor volume shrinkage of 53% within a month) but rapid re-expansion to its original dimensions one week after discontinuation of bromocriptine. To our knowledge, this is the first time that the rapid shrinkage/re-expansion of a macroprolactinoma has been documented with serial MRI scans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11383485     DOI: 10.1023/a:1011412028660

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  25 in total

1.  Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.

Authors:  J W van 't Verlaat; R J Croughs
Journal:  Clin Endocrinol (Oxf)       Date:  1991-03       Impact factor: 3.478

2.  Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.

Authors:  K Kovacs; L Stefaneanu; E Horvath; R V Lloyd; I Lancranjan; M Buchfelder; R Fahlbusch
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

3.  Immunohistochemical, electron microscopic, and morphometric studies of human prolactinomas after short-term bromocriptine treatment.

Authors:  J Niwa; T Minase; M Mori; K Hashi
Journal:  Surg Neurol       Date:  1987-11

4.  Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine.

Authors:  M O Thorner; R L Perryman; A D Rogol; B P Conway; R M Macleod; I S Login; J L Morris
Journal:  J Clin Endocrinol Metab       Date:  1981-09       Impact factor: 5.958

5.  The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.

Authors:  S G Soule; J Farhi; G S Conway; H S Jacobs; M Powell
Journal:  Clin Endocrinol (Oxf)       Date:  1996-06       Impact factor: 3.478

6.  Dopamine agonists and pituitary tumor shrinkage.

Authors:  J S Bevan; J Webster; C W Burke; M F Scanlon
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

7.  Effects of bromocriptine on prolactin-secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis.

Authors:  H Mori; S Mori; Y Saitoh; N Arita; T Aono; T Uozumi; H Mogami; K Matsumoto
Journal:  Cancer       Date:  1985-07-15       Impact factor: 6.860

Review 8.  Pituitary disorders. Drug treatment options.

Authors:  J J Orrego; A L Barkan
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

9.  Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal.

Authors:  C Wang; K S Lam; J T Ma; T Chan; M Y Liu; R T Yeung
Journal:  Clin Endocrinol (Oxf)       Date:  1987-09       Impact factor: 3.478

10.  Clinical and morphological findings in two cases of bromocriptine-treated prolactinomas.

Authors:  M Anniko; J Wersäll
Journal:  Acta Pathol Microbiol Scand A       Date:  1981-01
View more
  4 in total

1.  Cerebrospinal fluid leakage as complication of treatment with cabergoline for macroprolactinomas.

Authors:  R T Netea-Maier; E J van Lindert; H Timmers; E L Schakenraad; J A Grotenhuis; A R Hermus
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

Review 2.  Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.

Authors:  Miao Yun Xia; Xiao Hui Lou; Shao Jian Lin; Zhe Bao Wu
Journal:  Endocrine       Date:  2017-10-17       Impact factor: 3.633

3.  Clinical presentation and response to therapy in patients with massive prolactin hypersecretion.

Authors:  Susana Mascarell; David H Sarne
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

4.  Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?

Authors:  Sema Ciftci Dogansen; Ozlem Soyluk Selcukbiricik; Seher Tanrikulu; Sema Yarman
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.